Suppr超能文献

新型 2024 年世卫组织淋病奈瑟菌参考菌株,用于全球实验室调查的质量保证,取代世卫组织淋病奈瑟菌参考菌株 - 表型、遗传和参考基因组特征。

The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization.

机构信息

Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Microbiology, Örebro University, Örebro, Sweden.

Institute for Global Health, University College London (UCL), London, UK.

出版信息

J Antimicrob Chemother. 2024 Aug 1;79(8):1885-1899. doi: 10.1093/jac/dkae176.

Abstract

OBJECTIVES

MDR and XDR Neisseria gonorrhoeae strains remain major public health concerns internationally, and quality-assured global gonococcal antimicrobial resistance (AMR) surveillance is imperative. The WHO global Gonococcal Antimicrobial Surveillance Programme (GASP) and WHO Enhanced GASP (EGASP), including metadata and WGS, are expanding internationally. We present the phenotypic, genetic and reference genome characteristics of the 2024 WHO gonococcal reference strains (n = 15) for quality assurance worldwide. All superseded WHO gonococcal reference strains (n = 14) were identically characterized.

MATERIAL AND METHODS

The 2024 WHO reference strains include 11 of the 2016 WHO reference strains, which were further characterized, and four novel strains. The superseded WHO reference strains include 11 WHO reference strains previously unpublished. All strains were characterized phenotypically and genomically (single-molecule PacBio or Oxford Nanopore and Illumina sequencing).

RESULTS

The 2024 WHO reference strains represent all available susceptible and resistant phenotypes and genotypes for antimicrobials currently and previously used (n = 22), or considered for future use (n = 3) in gonorrhoea treatment. The novel WHO strains include internationally spreading ceftriaxone resistance, ceftriaxone resistance due to new penA mutations, ceftriaxone plus high-level azithromycin resistance and azithromycin resistance due to mosaic MtrRCDE efflux pump. AMR, serogroup, prolyliminopeptidase, genetic AMR determinants, plasmid types, molecular epidemiological types and reference genome characteristics are presented for all strains.

CONCLUSIONS

The 2024 WHO gonococcal reference strains are recommended for internal and external quality assurance in laboratory examinations, especially in the WHO GASP, EGASP and other GASPs, but also in phenotypic and molecular diagnostics, AMR prediction, pharmacodynamics, epidemiology, research and as complete reference genomes in WGS analysis.

摘要

目的

耐多药和广泛耐药淋病奈瑟菌菌株仍然是国际上主要的公共卫生关注点,因此进行有质量保证的全球淋球菌抗菌药物耐药性(AMR)监测至关重要。世界卫生组织全球淋球菌抗菌药物监测计划(GASP)和世卫组织强化 GASP(EGASP)正在国际上扩大,包括元数据和 WGS。我们展示了 2024 年世卫组织淋病参考菌株(n=15)的表型、遗传和参考基因组特征,以确保全球范围内的质量。所有已取代的世卫组织淋病参考菌株(n=14)均具有相同的特征。

材料和方法

2024 年世卫组织参考菌株包括 2016 年世卫组织参考菌株中的 11 株,这些菌株得到了进一步的特征描述,以及 4 株新菌株。被取代的世卫组织参考菌株包括以前未公布的 11 株世卫组织参考菌株。所有菌株均进行了表型和基因组特征(单分子 PacBio 或 Oxford Nanopore 和 Illumina 测序)分析。

结果

2024 年世卫组织参考菌株代表了目前和以前(n=22)或考虑用于未来(n=3)淋病治疗的所有现有敏感和耐药表型和基因型的抗菌药物。新的世卫组织菌株包括国际传播的头孢曲松耐药性、新型 penA 突变引起的头孢曲松耐药性、头孢曲松加高水平阿奇霉素耐药性以及镶嵌 MtrRCDE 外排泵引起的阿奇霉素耐药性。所有菌株均介绍了 AMR、血清群、脯氨酰肽酶、遗传 AMR 决定因素、质粒类型、分子流行病学类型和参考基因组特征。

结论

2024 年世卫组织淋病参考菌株推荐用于实验室检查的内部和外部质量保证,特别是在世卫组织 GASP、EGASP 和其他 GASPs 中,但也推荐用于表型和分子诊断、AMR 预测、药效动力学、流行病学、研究以及 WGS 分析中的完整参考基因组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cf2/11290888/89d771c50a8c/dkae176f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验